SEC Filings

Form 10-Q
CATABASIS PHARMACEUTICALS INC filed this Form 10-Q on 05/11/2017
Document Outline
Entire Document (2269.9 KB)
Subdocument 1 - 10-Q - 10-Q
Page 1 - UNITED STATES
Page 2 - TABLE OF CONTENTS
Page 3 - CAUTIONARY NOTE CONCERNING FORWARD-LOOKING STATEMENTS
Page 4 - PART I FINANCIAL INFORMATION
Page 5 - Catabasis Pharmaceuticals, Inc
Page 6 - Catabasis Pharmaceuticals, Inc
Page 7 - Catabasis Pharmaceuticals, Inc
Page 8 - Catabasis Pharmaceuticals, Inc.
Page 9 - Basis of Presentation and Principles of Consolidation
Page 10 - Equity
Page 11 - Leases
Page 12 - N/A
Page 13 - N/A
Page 14 - N/A
Page 15 - N/A
Page 16 - Employee Stock Purchase Plan
Page 17 - At-the-Market Financing
Page 18 - Item 2. Management s Discussion and Analysis of Financial Condition and Results of Operations
Page 19 - Pseudomonas aeruginosa
Page 20 - Edasalonexent -
Page 21 - N/A
Page 22 - General and Administrative Expenses
Page 23 - Research and Development Expenses
Page 24 - Credit Facility
Page 25 - Cash Flows
Page 26 - N/A
Page 27 - Off-Balance Sheet Arrangements
Page 28 - Item 3. Qualitative and Quantitative Disclosures about Market Risk
Page 29 - PART II OTHER INFORMATION
Page 30 - We have a limited operating history and no history of commercializing pharmaceutical products, which
Page 31 - Raising additional capital may cause dilution to our stockholders, restrict our operations or requir
Page 32 - Risks Related to the Discovery, Development and Commercialization of Our Product Candidates
Page 33 - Our SMART linker drug discovery platform may fail to help us discover and develop additional potenti
Page 34 - Because we are developing edasalonexent for the treatment of DMD, a disease for which regulatory aut
Page 35 - If clinical trials of our product candidates fail to satisfactorily demonstrate safety and efficacy
Page 36 - If we, or any future collaborators, experience any of a number of possible unforeseen events in conn
Page 37 - If we, or any future collaborators, experience delays or difficulties in the enrollment of patients
Page 38 - Even if one of our product candidates receives marketing approval, it may fail to achieve the degree
Page 39 - If we are unable to establish sales, marketing and distribution capabilities or enter into sales, ma
Page 40 - If the FDA or comparable foreign regulatory authorities approve generic versions of any of our produ
Page 41 - Product liability lawsuits against us could divert our resources, cause us to incur substantial liab
Page 42 - Risks Related to Our Dependence on Third Parties
Page 43 - We rely on third parties to conduct our clinical trials. If they do not perform satisfactorily, our
Page 44 - We contract with third parties for the manufacture and distribution of our product candidates for cl
Page 45 - Risks Related to Our Intellectual Property
Page 46 - If we are unable to protect the confidentiality of our trade secrets, the value of our technology co
Page 47 - If we are sued for infringing intellectual property rights of third parties, such litigation could b
Page 48 - Obtaining and maintaining our patent protection depends on compliance with various procedural, docum
Page 49 - We may be subject to claims by third parties asserting that our employees or we have misappropriated
Page 50 - Failure to obtain marketing approval in foreign jurisdictions would prevent our product candidates f
Page 51 - Any of our product candidates for which we, or any future collaborators, obtain marketing approval i
Page 52 - The efforts of the Trump Administration to pursue regulatory reform may limit the FDA s ability to e
Page 53 - Our relationships with customers and third-party payors, among others, will be subject to applicable
Page 54 - Anti-Kickback Statute.
Page 55 - Governments outside the United States tend to impose strict price controls, which may adversely affe
Page 56 - Risks Related to Employee Matters and Managing Growth
Page 57 - If we were to be delisted from The NASDAQ Stock Market, it could make trading in our stock more diff
Page 58 - We are an emerging growth company, and the reduced disclosure requirements applicable to emerging gr
Page 59 - We do not anticipate paying any cash dividends on our capital stock in the foreseeable future, accor
Page 60 - Our certificate of incorporation designates the state courts in the State of Delaware or, if no stat
Page 61 - Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Page 62 - SIGNATURES
Page 63 - EXHIBIT INDEX
Subdocument 2 - EX-31.1 - EX-31.1
Page 1 - Exhibit 31.1
Subdocument 3 - EX-31.2 - EX-31.2
Page 1 - Exhibit 31.2
Subdocument 4 - EX-32.1 - EX-32.1
Page 1 - Exhibit 32.1
XBRL Item - EX-101.INS - XBRL INSTANCE DOCUMENT (What's this?)
XBRL Item - EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT (What's this?)
XBRL Item - EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT (What's this?)
XBRL Item - EX-101.LAB - XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT (What's this?)
XBRL Item - EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT (What's this?)
XBRL Item - EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT (What's this?)
XBRL Viewer